Finding drugs that block the cancer-linked enzymes PLCγ1 and PLCγ2
Primary screening and hit follow up to identify the first selective inhibitors of PLC?1 and PLC?2
['FUNDING_R01'] · PURDUE UNIVERSITY · NIH-11263662
This project looks for new small-molecule drugs that specifically block the PLCγ1 and PLCγ2 enzymes to help people with cancers driven by these proteins.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PURDUE UNIVERSITY (nih funded) |
| Locations | 1 site (WEST LAFAYETTE, UNITED STATES) |
| Trial ID | NIH-11263662 on ClinicalTrials.gov |
What this research studies
Researchers will run a large laboratory screen using a new glowing chemical they developed to test 200,000 compounds for activity against the PLCγ1 and PLCγ2 enzymes. They will also use a membrane-like test (liposome-incorporated substrate) to better mimic how these enzymes work in cells. Promising hits will be retested, filtered to remove false positives and promiscuous binders, and followed up with additional lab studies. This is an early drug-discovery effort performed in the lab before any work with patients.
Who could benefit from this research
Good fit: In the future, ideal candidates for trials of any resulting drugs would likely be people whose tumors have activating PLCγ1 or PLCγ2 changes or cancers that rely on these pathways (for example certain leukemias or PD-L1–positive tumors).
Not a fit: Patients without cancers driven by PLCγ enzymes or those seeking immediate treatment are unlikely to benefit directly from this laboratory screening at this stage.
Why it matters
Potential benefit: If successful, this could lead to new targeted cancer drugs and make immune therapies like PD-L1 blockers work better for some patients.
How similar studies have performed: No selective PLCγ1 or PLCγ2 inhibitors are currently known, so this is a novel, early-stage preclinical discovery effort rather than a follow-up to existing clinical successes.
Where this research is happening
WEST LAFAYETTE, UNITED STATES
- PURDUE UNIVERSITY — WEST LAFAYETTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHANG, ZHONG-YIN — PURDUE UNIVERSITY
- Study coordinator: ZHANG, ZHONG-YIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.